

NEW!

Senvelgo 

Just what cats ordered

A convenient, once-daily, oral solution for diabetes



Senvelgo®'s novel approach means you can now treat diabetes without injecting insulin

- ◆ Simple dosing according to bodyweight
- ◆ Reduced risk of clinical hypoglycaemia
- ◆ Glycaemic control can be achieved within a week^{1,2}

Make Senvelgo® your new, simple solution for diabetic cats and their owners



Scan to
learn more!



Boehringer
Ingelheim

Watch our new Senvelgo® webinar and earn free CPD!

As part of the launch toolkit, this new Senvelgo® webinar 'How to manage diabetes in cats with Senvelgo®' is hosted by Dr Teen Presnail BVSc (Hons) CertVOphthal MRCVS, who will introduce you to Senvelgo®, our new breakthrough treatment for diabetes, and guide you through how to best use Senvelgo® to successfully manage feline diabetes in your practice.



Scan to watch
and earn
free CPD!

Senvelgo® toolkit

To support you with prescribing Senvelgo®, we have produced a new Senvelgo® toolkit which includes a veterinary management guide, CPD webinar, cat owner leaflet and homecare journal.



For more information and to access these materials, visit
senvelgo.vet

Veterinary support

A team of 8 vets and 5 veterinary nurses with over 140 years' combined experience.

Case discussions and product advice

UK: 01344 746957 IE: 01 291 3985

vetenquiries@boehringer-ingelheim.com

NEW live chat service

senvelgo.vet

Service hours

Mon-Thu 9am-5pm

Fri 9am-4.30pm

Emergencies 24/7 (via telephone only)

Virtual team meetings

A technical vet can attend a meeting via Microsoft Teams or Zoom



Best-in-class animal health pharmaceutical company for technical support helpline in 2022. CM Research 2022

Speak to your Boehringer Ingelheim Territory Manager for more information!

1. Niessen, S. J. M. et al. (2022) Once daily oral therapy for feline diabetes mellitus: evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. *Journal of Veterinary Internal Medicine* 36, 2512-2513.
2. Sparkes, A. H. et al. (2015) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. *J Feline Med Surg* 17, 235-50.
3. CM Research (2022) Small animal vets UK April 2022. Syndicated Sales Rep Survey.

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK(NI): POM-VIE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK(NI) Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Mar 2024. UI-PET-0030-2024. Use Medicines Responsibly.



**Boehringer
Ingelheim**